Ifunanya Okafor17 February 2025
The U.S. Food and Drug Administration (FDA) has approved GSK’s Penmenvy, a combination vaccine designed to protect individuals aged 10 to 25 against Neisseria meningitidis, the bacteria responsible for meningococcal infections. Penmenvy offers protection against five common strains of the bacteria serogroups A, B, C, W, and Y integrating components from GSK’s existing vaccines, Bexsero […]
